LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

3.3 -11.76

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.2

Max

3.76

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+198.41% upside

Turustatistika
By TradingEconomics
Turukapital	326M 873M
Eelmine avamishind	15.06
Eelmine sulgemishind	3.3

Uudiste sentiment

By Acuity

36%

64%

119 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. dets 2025, 15:21 UTC

Tulu

Correction to Home Depot Outlook Headline on Dec. 9

23. dets 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23. dets 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 21:21 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Hold Deposit in Escrow

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23. dets 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23. dets 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23. dets 2025, 19:13 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23. dets 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23. dets 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. dets 2025, 17:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23. dets 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23. dets 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23. dets 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank: Closing Expected Around Mid-January

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23. dets 2025, 16:02 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23. dets 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Receives Green Light for Acquisition in Poland

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica Doesn't Set Out Financial Details of Divestment

23. dets 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Deal Will Allow Focus on Core Markets

23. dets 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23. dets 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

198.41% tõus

12 kuu keskmine prognoos

Keskmine 11.25 USD 198.41%

Kõrge 15 USD

Madal 8 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

119 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.